Scott Rocklage: 5AM Venture Partner

Scott Rocklage has been Managing Partner of 5AM Ventures since 2004. Novartis Venture Fund, Kleiner Perkins, Alexandria Venture Investments, RA Capital Management, Sanofi Ventures, and 5AM Ventures have all taken part in generating money for Series A. Expansion Therapeutics raises money for Series A financing for combating genetic disorders. DM1, or Myotonic dystrophy type I, is one of the disorders that is being funded.

 

DM1 is the top cause of muscular dystrophy in adults. Expansion Therapeutics has added over $50 million to its cause in order to fight the disease. When RNA reaches high levels within the cells, symptoms of the disease show themselves. Consequently, the heart, muscles, central nervous system, gastrointestinal system, respiratory system, and the hormonal system all start becoming defective.

 

Sadly, the medical community doesn’t have a good treatment for DM1. That is why funding is needed for this particular disease. It doesn’t just affect families now, it affects succeeding generations. Expansion Therapeutics makes medications that challenge RNA illnesses. They particularly deal with repeat disorders in which hereditary illnesses don’t respond well to current medical treatments.

 

Scott Rocklage earned his Bachelor of Science degree in Chemistry at the University of California, Berkeley. He then received his Ph.D. in Chemistry from MIT. He has over 30 years of experience in healthcare management, as well as research experience.

 

Dr. Scott Rocklage has given FDA approval on Teslascan, Omniscan, and Cubicin medications. Over 30 U.S. patents have been co-invented or invented by him. He was once the CEO and Chairman of Cubist Pharmaceuticals and CEO and President of Nycomed Salutar. Currently, he is the Board Chairman for Rennovia, Kinestral, and Cidara. And, he now works in the Boston, Massachusetts office of 5AM Ventures.

 

Visit http://5amventures.com/team/scott-m-rocklage-phd/ to learn more.

Matthew Autterson:Accomplished Businessman Involved In Non-Profit

Matthew spent his younger years growing up in Detroit Michigan. In 1975, he graduated from Brother Rice High School, located in nearby Bloomfield Hills, Michigan. From there he went on to college at Michigan State University, where he graduated in 1980. His B.A. was in finance, which prepared him well for his future career. Matthew began working at First Trust Corporation early in his career, after attending the University of Denver’s Graduate Tax Program.

 

In 1982 he left this job for a new career objective, which was to be part of a team involved in chartering a Colorado State trust company. The new company was established as a subsidiary of Integrated Resources, Inc. A few years later in 1986, he was promoted to the position of President of Resources Trust Company. In 1989, Broad Incorporated acquired this company, along with some other assets owned by Integrated Resources. Later this corporation became known as SunAmerica, Inc. A few years later, in 1998 SunAmerica was acquired for $18 billion by AIG. Mr. Autterson’s successful career of 25 years in the financial services sector included his tenure as president of one of the US’s largest state charted financial institutions.

 

Matthew Autterson served on the Board of Directors of a nonprofit organization known as Falci Adaptive Biosystems (FAB). The mission of FAB is to help those individuals who are handicapped from neuromotor disabilities, so that with assistance, their ability to both interact with and control their environment would be enhanced and improved

 

Falci Adaptive Biosystems (FAB) was the main nonprofit organization that Matthew Autterson participated in, that was located in Colorado’s business community. Mr. Autterson has been a long-time influential and respected business leader there. His nonprofit service included several years in Denver’s Zoological Foundation, as well as on the Board of the Denver Zoo. In addition, he spent time serving on the Board of Directors as Chairman of Denver Hospice. See This Page for additional information.

 

Today Matthew Autterson is employed at GL3B Partners Limited, LLP, where he has been since 2001. He is a managing partner of the company, and currently resides in Cherry Hills Village, Colorado. He is also the President and Chief Executive Officer of CNS Biosciences, Inc., where he has worked since 2013. Located in Englewood, Colorado, this company was started in 2013 by Dr. Scott Falci. The corporation is a drug development company that has a mission of discovering neuropathic drugs for pain, focusing on early and clinical stage drug development.

 

See Also: https://www.blacktie-colorado.com/photos/photodetail.cfm?id=495

Matthew Autterson A Man of Many Hats

Matthew Autterson born in Detroit Michigan is the prestigious President and Chief Executive Officer of CNS Bioscience Inc. since 2013. Matthew resides in the state of Colorado and is a leader in the business community.

 

Matthew Autterson Past and Present Volunteer Experience

Member of the Board of Directors

Company: Falci Adaptive Biosystems

Business Field: Science and Technology

2013 – Present

 

Chairman of the Board of Directors

Company: The Denver Hospice

Business Field: Health

1987-2002

 

Denver Zoo Board Representative

Company: Denver Zoological Foundation

Business: Animal Welfare

1998-2008

 

Member of the Board of Directors

Company: Webb-Waring Foundation

Business: Science and Technology

1996-1998

 

Matthew Autterson Education

University of Denver

Graduate Tax Program

Studies: Tax Program

1981-1981

 

Michigan State University

Degree: Bachelor of Arts

Studies: Finance

1975-1979

 

CNS Bioscience

CNS is a clinical phase drug development company. CNS main focus is relieving neuropathic pain. Neuropathic pain may describe as a burning pain or shooting pain caused by various medical conditions. CNS Bioscience is a company dedicated to assisting patients with all options of medications on a clinical trial bases to relieve them of their pain discomfort. The more patients that participate in trying new medications through CNS, pharmaceutical client contact, the more CNS strive to produce more services for their clients and patients. Mr. Autterson enjoys helping people in the best way of a person’s needed assistance. The industry of clinical trial is a delicate subject matter and comes with risk, but Mr. Matthew Autterson is confident that his business will grow and resources will be plentiful to assist people who he is helping through the CNS Bioscience business.

 

Matthew Autterson Philanthropist

Matthew proudly gives back to the community of Denver. Mr. Autterson current philanthropic interest is as follow.

  • Board of Denver Zoo
  • Denver Zoological Foundation
  • Chairman of the Board of Directors of Denver Hospice

Refer to This Article for more information.

Matthew Autterson has been part of Denver’s philanthropic circle since 2000. Matthew’s first fundraiser was an event named “The Do at the Zoo’ Matthew secured $50,000 towards the proceeds to purchase a children’s carousel. Matthew’s philanthropic contributions became more impressive after learning what to do at a “Do” Mr. Autterson attended this event for 11 years before the attendance diminished from 2,500 guests to 325 guests.

 

Matthew Autterson at the end of the Day

Matthew Autterson is a very successful businessman with several responsibilities which he acquired through the knowledge and the know-how from education and work experience and life experience. One might say that Mr. Autterson with business leadership and social leadership along with other activities and various interests is a man of many hats. Matthew at the end of the day is just Matt on his way home to his loving family in Cherry Hills Village, Colorado one the most affluent places in Colorado and the United States.

Learn More: https://www.business.com/advice/member/p/matthew-autterson/